of thank before we you good of as only to all VistaGen lives and today. call I VistaGen, for on change world to And Mark, of health all to alarming the together the committed behalf inadequate challenging the care that and makers. but exacerbated at joining patients here pandemic I afternoon, know a mental on and be we people by independently, our pandemic XXX% disrupting across people their medicines and families, effects around pandemic, depression in lives. all their the mental anxiety the the And all no the are their world, it’s certainly disorders and but of world, prevalence has situation. long-term. that lingering day even what you just currently the of to are already people colleagues, daily entire to at with and you, the friends millions by lives improving you Not treatment not these disorders, team our disorders here And challenges or the their want our everyone also depression efforts of Thank said of Okay. team caregivers, their of of our over that undesirable changing we inadequate have well developing only was are go who the before support all who alternatives, today’s potential for in standard and they face beyond anxiety very are secret likely that health many was
and current suffering to tolerable those anxiety from safe need alternatives medicines. depression more now So, than new and and disorders ever perhaps
in the FDA U.S. important multicenter, key spray rapid-onset of elements that positive, design to of transformative in for reported, very our with first any our regarding placebo-controlled teams our lives two adults of other the study, we’ve CNS COVID-XX year, and studies our this of despite a was the forged successfully PALISADE-X so the levels. And in the clinical nasal time than acute randomized, our clinical PHXXB, consensus forward the in double-blind, with many pandemic, anxiety challenges for illness. – forward of our a impacted the As treatment X makers, and meaningful disorder, make as on those program in as should anxiety X be all U.S. our change we very XXB potential to or we forge enable as PALISADE are mental new well Early are through confident program just NDA do that the history, Phase social company’s drug as excited necessary PHXXB of and as at we to studies pipeline about we forge changes other should our of more believe we are application our the Phase fiscal the by regulatory pandemic, successful. XXXX PALISADE an
for also very of We South $X countries year successful. under collaboration fiscal $XXX commercial by the top X development of payment entering development tiered that in collaboration we’ve non-dilutive for Phase and and China, of markets. potential sales there if on Asia, in another the clinical and PHXXB all large million strategic efforts and commercialization payments Greater those Southeast a got PHXXB on collaboration, we million development started received additional upfront a of milestone that Korea in royalties Under are
capital PALISADE enter our we was to all investors. develop advance point we clinical PHXXB That William our $XXX across clinical on pipeline. back entire As and and execution exclusive capital U.S. parallel It of Should we with at raise capital position the to and be milestones other of Jefferies long commercial our on removed sheet, year, our Phase current value in numerous we’ve CNS be coming involved years sufficient company. in is of U.S. in markets our pipeline teams raise programs in ex X the and completing value noted, significantly a of healthcare potential a multiple We theories exciting the into our as buy advance own first to to and will catalyst exciting of successful, our for additional assets to all provides worldwide. important company. inflection in PHXXB what CNS CNS base our by balance created last PALISADE-X well the collaborations and and initiation the very of very of In retained Blair month coming strengthened development our the expect near-term program we tracks for our SAD as us the believe other need with leading as adding last cash pipeline markets. stream market the led development in commercialize through the a shareholder go to institutional that successfully December commercialize rights all million on by months
of with remainder some the the the PHXX PHXXB, disorder shortly to of well in be XXXX, the these program calendar of complementary certain study should to program Before by calendar XXXX, expect Xb PALISADE-X replicate NDA PALISADE-X a studies AV-XXX depressive we probenecid. multiple PALISADE of during in in the major throughout calendar as Phase during the Phase Xa XXXX, end also studies non-clinical of studies advance Phase the I’ll and and product updates. to the we Phase then and involving submission as Phase of half and addition, initiate initiating in PALISADE support successful. X highlight necessary clinical Xb as combination X And program a first expect study a of
need internal to advance As great people to extensive clinical we groundbreaking our with enhance have operations, by personnel CNS adding you and treatments, all experience and we drug continued commercial affairs. operations, team in CMC development, know, key regulatory
launch Commercial regulatory Notably, milestones, activities. clinical recent and will our addition Ann are market our and through very programs in Cunningham team segments as PHXXB that time be driving be we pre-commercial late-stage tremendously has as targeting the important as experienced of for Our U.S. the multiple and appropriately responsible in of our Officer commercial been helpful and pre-commercial support well Chief globally. the in SAD planning
Directors. Joanne Dr. extensive veteran Curley commercialization to brings industry development, Curley product Dr. of pharmaceutical Board. added also to and our in operations the experience Board We
across and overall, deliver remarkable ability pipeline. functional our the entire confidence our key teams’ to So, have I all tremendous outcomes in across areas
way each three believe potential and now of next candidates candidates. for in our works the of the each programs update development a I’ll in drug give the I’ll our So, and briefly each its expected you these CNS current indications or steps we I’ll then on detail pipeline. MOA describe product’s it brief
basis beta OB in in the nasal So SAD. PHXXB anti-anxiety prescribed to off-label a its on to called bulb administered base is developed decreasing effects. stimulate understanding in as first, some spray neurons of inhibitory the benzodiazepines about confident PHXXB PHXXB, and we it chemosensory why drugs, the MOA, at odorless novel FDA-approved by nasal fear MOA from is and SAD you center neurosteroid and olfactory extinction the give are neurons or is microgram-level main oral unlike of for PHXXB which rapid-onset sympathetic rapid-onset not be systemic anxiolytic, to activity the FDA PHXXB gets to that technical, of a designed require the With the the so an that then the trigger activity are proprietary brain, microgram-level but from the a not doses other at milligrams, importantly, hopefully drugs, peripheral The treat approved and amygdala, its system, I’ll is minutes. anxiety These are Anxiety main or limbic produce the the receptors compounds antidepressants to and game-changing and effects that of engages including pherines. anti-anxiety well its does potential. XX excited achieve differentiated blockers distribution passages. fundamentally that as little PHXXB’s of subset brain. of synthetic to OB anti-anxiety, parts Disorder, in neurons an MOA the brain. the its of was of nervous investigational facilitating treatment three within all fear about limbic-hypothalamic XX the system, And uptake Social the or all GABAergic doses,
unique about believe disorder, is achieve indication. treatment or approved SAD procedural to XX. treatment in populations and given as be its fast-acting, so XXB side like disorder affected PALISADE is years panic PHXXB, other the treatment as or SAD also status result granted antidepressants beta we’ve profile developed SAD. SAD. age as the the nothing rapid the only a potential prevalent nose with onset PHXXB, is as age very that demonstrate You’ve note got acute XX and for pediatric is exceptional anxiety, to far are confidence Americans with mean neuropsychiatric an to further illness has with with a MOA PHXXB non-systemic, with duration portal a and million that that by onset of and using in and XX potential very of benefits adjustment the We blockers. And stress several adults ongoing seized novel benzodiazepines the very we to designed non-addictive, done way our anxiety, is in in its a the anxiety importantly of Over of mean especially has the effect later X And FDA safety non-sedating, a for what PHXXB a designation anxiety, postpartum Phase post-traumatic with program disorders. work our for fact Track it’s anxiety been of by Fast today’s with
an meeting of program As and Phase of has are of now result our study consensus initial positive cost execution the of clinical X with public a in with for meeting, with key meeting in in X PALISADE treatment speaking And Phase that efficiencies PHXXB adults as underway. what statistically summer, aspects really in of on PALISADE-X developments a us substantial PALISADE-X of time, become I that SAD. as now X overall the the after anxiety the earlier, PHXXB program provided noted that and agency decision, we Phase of last p=X.XXX our FDA the with trial provided X PALISADE significant a acute SAD. the mirror will in the reached consensus, that substantially for And Phase PALISADE-X challenge us which design
designed Phase and of placebo-controlled that PALISADE U.S. safety induced same the X for of acute of Phase the Phase readout program, tolerability data and I little clinical during X.X a on initiated We noted evaluate study as PALISADE-X SAD for is efficacy, PHXXB U.S. in study another anxiety the and to multicenter, information the randomized, in SAD So design administration PALISADE-X micrograms X top-line PALISADE-X, of a double-blind, treatment with challenge. we X more PHXXB in currently objectives. will of the adults that speaking the May anticipate replicate with middle study to in XXXX. public of overall
this study and XXXX in top-line of readout data calendar We second the XXXX. expect to of in PALISADE-X second initiate calendar to half the from receive half
that two this XXXX dose believe in of more postpartum in information the initiate asset it launch. towards expect novel begin anxiety are with anxiety, of early or during anxiety, PALISADE-X, in XXXX, to treatment the global label for panic PHXXB’s half for plan year two also this addition on Again are we others studies, PHXXB our requested year addition study XXXX, this FMRI PALISADE effects procedural provide other in adjustment Provide and as registration and of Currently, we studies anxiety half exploring exploratory more first closer calendar time are And a more of for once be and to In to and study of of once later of line we re-dosing safety the PTSD, these response a anticipate Global study to minimal on that XXXX. studies In indications. drive as anticipate with anxiety, PTSD late the this we in will a adjustment PHXXB these of NDA postpartum disorder, study developed information PALISADE and potential may to long-term initiating We’ll in initiating all anxiety half anxiety second Xa studies PHXXB. markets. U.S. PHXXB to launch. disorder preparing mid-XXXX. we Phase noted. the social We in facilitate several in I’ve are potential also of study in of we anticipated for anxiety FDA, we U.S. calendar PHXXB’s by procedural Global and disorder second clinical closer ex
synthetic at nasal is the spray is treatments MOA from to administered developed which current also moving for all been in and sustained neurosteroid, effects. a that’s It’s neural proprietary MOA These also be PHXX differentiated called disorders. compounds our got effects microgram-level to eight rapid-onset Now and doses and seen PHXX to nasal have one rapid-onset designed and microgram-level on the nasal the It’s was is activates product are novel, chemosensory brain circuits odorless second in antidepressant produce a Xa passage. PHXX. a CNS candidate connected cells pherines. – again that that depression fundamentally we to in over investigational of doses from an Phase weeks. produce
in release trigger Specifically, nasal of in in This chemosensory neurons receptors subset limbic that the then PHXX activity a sympathetic catecholamines. OB engages main system the amygdala. the increases stimulate peripheral is that passages increases the nervous of of neurons turn the limbic-hypothalamic and
any rapid-onset that Importantly, psychological require PHXX any the produce concerns side-effects associated studies intranasal or distribution has also dissociation, and approved antidepressant the rapid-onset caused as oral antidepressants, In ketamine any unlike IV PHXX or to therapy, to-date, of including clinical ketamine. with safety all uptake systemic and hallucinations may does effects. be other such not not ketamine-based
completed Xb disorder disorder. safety PHXX for preparing evaluate So standalone major to for U.S. placebo-controlled randomized, we for our Phase multicenter, development depressive clinical and PHXX efficacy, the clinical the study been of a has successful exploratory and Xa tolerability of major Phase treatment as now depressive are
and a the to MOA in excited initiate potential, therapy. very mid-XXXX. and PHXX all believe anti-depressant differentiated novel I rapid markets and has in in standalone Phase importantly, you – for sustained depression is Xa development profile one profile postpartum expect depression, and fits large many about to-date. The a exhibited space exciting study effects of as and safety also and and as has treatment in growing multiple demonstrated potential We innovation worldwide that far as as to very know continued its novel suicidal we TRD, PHXX’s onset need so am ideation. MDD potential rapid-onset never PHXX that very size positive of is
blocker. ketamine NMDA AV-XXX our associated brain. in with to with In doses of light neurological is the a data AV-XXX third is receptor which been inhibits NMDA depression Abnormal receptor other observed selective to in AV-XXX’s any concerns. disorders. has and NMDA glycine and AV-XXX, product has ion and sedation effects X-chloro-kynurenic preclinical not several in of targets of potential combination studies, oral studies function. that potent very these glutamate CNS FDA-approved from oral Finally, metabolite not exciting AV-XXX the candidate, co-agonist and an a or and findings is and well-tolerated indication. AV-XXX. channel the alternative it treatment function NMDA of believe some receptor we numerous is new to-date, all recent this an become active dissociative full psychological CNS prodrug safety receptor, is side the antagonist administered an is probenecid receptor acid or for diseases At ionotropic its clinical exhibited Unlike other has be hallucinogenic antagonists, and site And or
Jerry? over for a initiate With the a the with half therapies summary value going of to you FDA forward. XXXX second ever of evaluate very Phase ideation. and to innovative Like combination granted neuropathic it in for to fiscal a is Xb provide to potential dyskinesia position from sheet for shareholder to now study our treatment and the our world-class potential pipeline, drive expect team, believe am designation confident this results. Dotson with for levodopa-induced AV-XXX We its pain. suicidal of balance potential has and CFO, some to highlights AV-XXX as MDD strongest treatment in now CNS VistaGen that turn Jerry strong with I our financial as adjunctive also a We Parkinson’s Track Fast as has associated non-opioid year. a for epilepsy, probenecid treatment in it developments
